RT Journal Article
SR Electronic
T1 Trends in SARS-CoV-2 seroprevalence among pregnant women attending first antenatal care visits in Zambia: a repeated cross-sectional survey, 2021-2022
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.01.02.24300729
DO 10.1101/2024.01.02.24300729
A1 Heilmann, Elizabeth
A1 Tembo, Tannia
A1 Fwoloshi, Sombo
A1 Kabamba, Bupe
A1 Chilambe, Felix
A1 Kalenga, Kalubi
A1 Siwingwa, Mpanji
A1 Mulube, Conceptor
A1 Seffren, Victoria
A1 Bolton-Moore, Carolyn
A1 Simwanza, John
A1 Yingst, Samuel
A1 Yadav, Ruchi
A1 Rogier, Eric
A1 Auld, Andrew F.
A1 Agolory, Simon
A1 Kapina, Muzala
A1 Gutman, Julie R.
A1 Savory, Theodora
A1 Kangale, Chabu
A1 Mulenga, Lloyd B.
A1 Sikazwe, Izukanji
A1 Hines, Jonas Z.
YR 2024
UL http://medrxiv.org/content/early/2024/01/03/2024.01.02.24300729.abstract
AB Background SARS-CoV-2 serosurveys help estimate the extent of transmission and guide allocation of COVID-19 vaccines. We measured SARS-CoV-2 seroprevalence among women attending ANC clinics to assess exposure trends over time in Zambia.Methods We conducted repeated cross-sectional surveys among pregnant women aged 15-49 years attending their first ANC visits in four districts of Zambia (two urban and two rural) during September 2021-September 2022. Serologic testing was done using a multiplex bead assay which detects IgG antibodies to the nucleocapsid protein and the spike protein receptor-binding domain (RBD). We calculated monthly SARS-CoV-2 seroprevalence by district. We also categorized seropositive results as infection alone, infection and vaccination, or vaccination alone based on COVID-19 vaccination status and anti-RBD and anti-nucleocapsid test results.Findings Among 8,304 participants, 5,296 (63.8%) were cumulatively seropositive for SARS-CoV-2 antibodies. SARS-CoV-2 seroprevalence primarily increased from September 2021 to September 2022 in three districts (Lusaka: 61.8-100.0%, Chongwe: 39.6-94.7%, Chipata: 56.5-95.0%), but in Chadiza, seroprevalence increased from 27.8% in September 2021 to 77.2% in April 2022 before gradually dropping to 56.6% in July 2022. Among 5,906 participants with a valid COVID-19 vaccination status, infection alone accounted for antibody responses in 77.7% (4,590) of participants.Interpretation Most women attending ANC had evidence of prior SARS-CoV-2 infection and most SARS-CoV-2 seropositivity was infection-induced. Capturing COVID-19 vaccination status and using a multiplex bead assay with anti-nucleocapsid and anti-RBD targets facilitated distinguishing infection-induced versus vaccine-induced antibody responses during a period of increasing COVID-19 vaccine coverage in Zambia. Declining seroprevalence in Chadiza may indicate waning antibodies and a need for booster vaccines. ANC clinics have a potential role in ongoing SARS-CoV-2 serosurveillance and can continue to provide insights into SARS-CoV-2 antibody dynamics to inform near real-time public health responses.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNAClinical ProtocolsNAFunding StatementThis research was financially supported by the Centers for Disease Control and Prevention (CDC) Emergency Response to the COVID-19 pandemic and the President’s Emergency Plan for AIDS Relief (PEPFAR) through the CDC under the terms of cooperative agreements with the Centre for Infectious Disease Research in Zambia (5 NU2GGH002251-02-00) and the Public Health Institute (5 NU2GGH002093-05-00). No additional external funding was received for this study. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was authorized by the National Health Research Authority (NHRA) through an expedited review of COVID-19 related studies. For Chadiza District, the SARS-CoV-2 data collection and serologic testing were reviewed and approved by the University of Zambia Biomedical Research Ethics Committee as an amendment to a pre-existing malaria surveillance protocol. This activity was reviewed by CDC and was conducted consistent with applicable federal law and CDC policy (See e.g., 45 C.F.R. part 46.102(l)(2), 21 C.F.R. part 56 42U.S.C. §241(d) 5 U.S.C. §552a44 U.S.C. §3501 et seq). All methods were carried out in accordance with relevant guidelines and regulations. Written informed consent was obtained for all participants before enrollment. Pregnant women under 18 years are considered emancipated minors in Zambia for the purpose of providing their own informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not Applicable